Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Cognex

Known as: Horizon Brand of Tacrine Hydrochloride, OTL Pharm Brand of Tacrine Hydrochloride, Parke Davis Brand of Tacrine Hydrochloride 
National Institutes of Health

Related topics

Related topics

2 relations
Romotal

Broader (1)

Tacrine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
rotl: an R package to interact with the Open Tree of Life data
Summary While phylogenies have been getting easier to build, it has been difficult to reuse, combine and synthesize the… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2015
Highly Cited
2015
A permanent, asymmetric dust cloud around the Moon
Interplanetary dust particles hit the surfaces of airless bodies in the Solar System, generating charged and neutral gas clouds… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2013
2013
Impact of loading displacements on SLR-derived parameters and on the consistency between GNSS and SLR results
Displacements of the Earth’s surface caused by tidal and non-tidal loading forces are relevant in high-precision space geodesy… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2008
Review
2008
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Dementias have become a major public health concern because of their increasing prevalence, chronicity, caregiver burden, and… Expand
Review
2008
Review
2008
Cholinesterase inhibitors for delirium.
BACKGROUND Delirium is now the preferred term to describe acute confusional states. It is experienced by 10 to 30% of all… Expand
2000
2000
Kinetic analysis of the toxicological effect of tacrine (Cognex) on human retinal acetylcholinesterase activity.
For the first time, kinetic parameters of the effect of tacrine, an anti-cholinesterase inhibitor of therapeutic potential in… Expand
Highly Cited
2000
Highly Cited
2000
Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.
Inhibitors of the enzyme acetylcholinesterase (AChE) slow and sometimes reverse the cognitive decline experienced by individuals… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1998
Highly Cited
1998
Safety of Tacrine: Clinical Trials, Treatment IND, and Postmarketing Experience
Summary:The safety of tacrine (Cognex'), a centrally active, reversible acetylcholincsterase inhibitor approved in 1993 for the… Expand
Highly Cited
1996
Highly Cited
1996
Long-term tacrine (Cognex) treatment
Objective: To assess the possible association between tacrine (Cognex, manufactured by Parke-Davis, Morris Plains, NJ) dose and… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Review
1994
Review
1994
Tacrine: First Drug Approved for Alzheimer's Disease
  • M. Crismon
  • The Annals of pharmacotherapy
  • 1994
    • Corpus ID: 21412096
OBJECTIVE: To review the pharmacology, biopharmaceutics/pharmacokinetics, clinical efficacy, adverse effects, and therapeutic… Expand
  • table I
  • table 2
  • table 3
  • table 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE